Cannabis: Legalizing the Leaf
What this covers
This Business Breakdowns episode has Jeff walk through the US cannabis industry with co-host Jeff Hoffman, moving from the plant's legal history to how operators make and keep money. Much of it concerns MSOs: why each state works like its own country, why plant-touching businesses face heavier banking compliance than distributors or manufacturers, and why operators with gross margins of at least 50 percent still pay effective tax rates of 50 to 70 percent. A recurring correction is that Canadian LPs such as Canopy Growth are not comparable to US operators.
The range extends beyond finance. Jeff argues that the 1970 placement of cannabis in Schedule I beside heroin does not hold up against how OxyContin or cocaine are scheduled. He cites a 2020 Florida patient study and notes that about 95 of the plant's 100-plus cannabinoids are poorly understood. His comparisons of cannabis with alcohol and opioid deaths are contested. On demand, he points to monthly use of about 10 percent versus 55 to 60 percent for alcohol, older consumers adopting low-dose edibles, and cannabis as an alcohol substitute at ballgames and concerts.
Politics and investing close it out. SAFE Banking has passed the House five times, while the broader MORE Act drew little Republican support. Jeff blames an older Senate for stalled comprehensive reform. Hoffman expects strategic acquirers to consolidate quality operators once federal law allows. Jeff describes spotting weak operations on facility tours and advises most retail investors toward ETFs.
Jeff argues US cannabis multi-state operators are structurally mispriced because federal illegality keeps them off major US exchanges and away from institutional capital, so limited-license, vertically integrated operators trade cheaply against their growth, with SAFE Banking as the likely catalyst.
- Federal illegality blocks NYSE and NASDAQ listings and makes institutional custody impractical, leaving the stocks on Canadian exchanges with thin liquidity
- Limited-license state structure caps competition, supporting high wholesale margins and lower acquisition prices
- SAFE Banking would give banks cover to serve the sector and unlock a re-rating
MSOs capturing the full seed-to-sale chain will earn most new cannabis economics and valuation premiums.
- Because private equity cannot lever up 5 to 6 times to buy US cannabis operators, the buyer pool is thin, so MSOs buying subscale operators pay around 3 to 4 times EBITDA, a low multiple in a fast-growing industry.
“Private equity is not coming in levering up 5X, 6X to buy, and then no one else can really buy”
- Canadian producers must sell to provincial authorities that resell to retailers, so they lose margin, whereas US MSOs can capture the entire seed-to-sale supply chain.
“the producers in Canada have to sell to providences who then sell to retailers. So they're getting cut out of the economics”
- In 2021, multi-state operators generated roughly 9 to 10 billion dollars in sales, and as Virginia, Connecticut, New York, and New Jersey open, most of the new economics will accrue to MSOs.
“2021, maybe 9 to 10 billion dollars of sales went to these multi-state operators”
- Canadian licensed producers such as Canopy Growth and Tilray have no US operations, negative free cash flow, and negative EBITDA, so comparing them to US MSOs is a factual mistake that investors often make.
“the Canadian cannabis companies have no earnings, they're negative free cash flow, negative EBITDA”
- There are tens of thousands of cannabis businesses but only about 50 publicly traded US cannabis companies, so the investable universe should grow over time as more public companies emerge.
“There's only about 50 publicly traded US cannabis companies.”
- Canadian cannabis producers have negative EBITDA and free cash flow, so revenue multiples are the only meaningful valuation tool, and on that basis US MSOs trade at a discount to Canadian peers despite a larger market.
“the Canadian cannabis companies have no earnings, they're negative free cash flow, negative EBITDA”
Alcohol substitution and state legalization choices will drive cannabis consumption growth, with health benefits.
- Cannabis is addictive and listed in the DSM, but it is very hard to die from it, with recent studies linking about 95,000 deaths annually to alcohol and about 50,000 to opioids, versus far fewer for cannabis.
“95,000 linked alcohol deaths annually, 50,000 opioid linked deaths annually”
- A 2020 Florida study found that 65 percent of medical cannabis patients reported reducing or discontinuing at least one prescription or over-the-counter drug, and 80 percent reported good or complete relief across symptom categories.
“65% of patients report either a reduction or total discontinuation, about at least one prescription or over the counter drug”
- In a mature cannabis market, about 50 percent of sales are flower and pre-rolls, 30 percent vapes, and 10 percent edibles, with concentrates making up the remainder, while medical markets lean more heavily toward inhaled flower.
“in a more mature market, about 50% of the basket is flower and pre-rolls, 30% vape, 10% edibles”
- Cannabis-infused beverages and flower sold at ballgames and concerts could displace alcohol because they avoid hangovers and heavy calories, and Jeff expects on-premise cannabis consumption to grow like alcohol does.
“you're going to go to a baseball game, you're going to buy a beer that's infused with THC”
- A recent survey found that among the 40 percent of consumers who use both cannabis and alcohol, 44 percent preferred cannabis and 30 percent preferred alcohol.
“of the 40% of folks who consume both cannabis and alcohol, 44% preferred cannabis, 30% alcohol”
- The cannabis plant contains over 100 cannabinoids, but about 95 of them are poorly understood because federal illegality makes research difficult, so future research may reveal uses that are very different from current ones.
“There are over 100 cannabinoids in the plant. Due to federal illegality and a very difficult time for folks to research the product”
- Only about 10 percent of consumers use cannabis monthly, compared with 55 to 60 percent for alcohol, which Jeff sees as evidence of substantial room for growth.
“only about 10% of consumers consume cannabis monthly versus 55 to 60% for alcohol”
- Governors such as Pennsylvania's are pushing legalization because their residents otherwise buy cannabis in neighboring legal states like New York and New Jersey, so border leakage and tax revenue motivate more states to legalize and build supply ahead of sales.
“Why should his citizens go to New York and New Jersey when they open up sales”
- Colorado's per-capita cannabis revenue exceeds 400 dollars, while California's is far lower because of too few dispensaries and an approximately 40 percent tax rate, compared with about 20 percent in Massachusetts, so tax design drives consumer spending.
“you're paying a 40% tax rate. That's crazy. If you go buy pot in Massachusetts, you're paying a 20% tax rate”
- Recent slow sequential growth reflects the end of stimulus checks and people returning to normal life, which Jeff views as a temporary hangover, with the long-run outlook including cannabis beverages at baseball games and concerts.
“I think this hangover is well deserved, but over the long term, nothing in my mind said this industry is not going to be gargantuan.”
- Many consumers who previously drank alcohol daily now barely drink because cannabis replaces it without hangovers or aggression, and this substitution is what will change public opinion.
“I know so many people who used to consume alcohol every single day and now they barely consume alcohol.”
- Cannabis consumption is associated with less binge drinking and less opioid use, which Jeff presents as evidence of substitution effects.
“It is shown that when people consume cannabis, there's less binge drinking, less opioid use.”
- New York, New Jersey, and Connecticut adult-use sales and eventual federal legalization are needed to remove the lazy-man stigma around cannabis, which Jeff believes is factually incorrect.
“They always thought it was this lazy man's drug. Factually incorrect.”
Licensed channels can grow the market by converting illicit consumers and new users.
- The US cannabis industry is roughly a $100 billion market, of which about $25 billion is legal and about $75 billion is illegal, so the core opportunity is moving existing illicit consumers into legal channels.
“it's a $100 billion industry today, which $25 billion is legal and $75 billion is illegal”
- COVID-era lockdowns and anxiety pulled cannabis demand forward, and legal dispensaries captured new consumers who shifted from illicit dealers to curbside and legal channels.
“COVID created a massive pull forward of demand, people were locked in their homes, they were anxious, they were scared”
- The legal US cannabis market could grow to well over $100 billion over the next decade, from about $11 billion in 2019, as adult-use sales launch in more states.
“this industry is going to be well over a $100 billion legal industry over the next decade. In 2019, it was an $11 billion industry”
- Illinois legalized adult-use cannabis on January 1, 2020, and its run rate reached about 2 billion dollars annually by late 2021, with about 30 percent of sales to out-of-state residents and cannabis tax revenue exceeding alcohol within two years.
“we're run rating as of this past December at about $2 billion in legal cannabis sales of which 30% of those sales come from out of state residents”
- Older consumers who view smoking as unhealthy are adopting low-dose edibles, and this demographic shift in consumption habits will expand the market substantially.
“people of different demographics, of older demographics are going to come into the category and consume edibles and seltzers. They don't want to smoke flower”
Vertically integrated multi-state operators capture margins that subscale retailers and growers lack.
- Multi-state operators are expected to grow about 50 percent in 2022, versus about 20 percent for the overall market, because limited-license states going legal over the next few years benefit them most.
“these cannabis companies, these MSOs, they're going to grow about 50% in 2022 versus the market which should grow probably at about 20% in 2022”
- Subscale retailers earn about 45 to 50 percent gross margin and 20 to 25 percent four-wall contribution, while scaled MSOs running efficient retail can reach about 35 percent all-in margins.
“the retailer, if they're subscale is probably generating 45% gross margins, maybe 50%”
- A grower in New Jersey selling wholesale at about 2,500 dollars per pound is cut out of the 5,000 dollar retail price when a third-party dispensary sells it, but a vertically integrated operator that grows for about 700 dollars and sells through its own stores captures the full markup.
“if you're selling third party, let's say you're in New Jersey and you're selling $2,500 per pound. The retailer, the third party is going to sell that for $5,000 a pound”
- Wholesale indoor cannabis growers have an all-in cost of about 700 dollars per unit, and in limited-license states they can generate 60 to 80 percent EBITDA margins depending on wholesale pricing and yield per square foot.
“We can generate 60 to 80% EBITDA margins depending on the limited license state you're in”
Federal illegality keeps cannabis companies off major exchanges and away from institutional capital.
- Because cannabis remains federally illegal, US exchanges such as the NYSE and NASDAQ will not list US cannabis companies without some form of federal protection, so most MSOs are relegated to Canadian Securities Exchange listings.
“the NYC and NASDAQ, the major exchanges will not allow these shares to trade on their exchanges without protection from the federal government”
- Scaled MSOs trade around 8 times 2022 EBITDA while growing 40 to 50 percent, and about 4 to 5 times 2024 EBITDA once new legal states come online, which makes them cheap relative to Canadian cannabis companies that have negative cash flow.
“these multi-state operators on average are trading at eight times 2022 EBITDA growing 40 to 50%”
- The top five MSOs have a combined market cap of about $20 billion but trade only about $60 million in aggregate per day, while Canopy Growth, a Canadian producer with about $4.5 billion market cap, trades about $70 million per day.
“The top five multi-state operators have a cumulative market cap of $20 billion, but only trade $60 million in aggregate a day”
- Prime brokers and institutional compliance departments generally refuse to custody or trade US cannabis stocks because of federal illegality, so only about 4 percent of MSOs are owned by institutions.
“about 4% of MSOs are owned by institutional holders”
- Large tobacco and alcohol companies such as Altria, British American Tobacco, Molson Coors, and AB InBev hold stakes in Canadian producers mainly to learn the business, and Canadian producers are buying US companies through options contingent on federal legality, since US holders cannot consolidate because federal illegality would trigger delisting.
“they're buying the options today to take it over to the future”
- Average retail investors should buy cannabis ETFs because the diligence needed to avoid bad actors and judge facility quality is extreme, though bottom-up investors who visit facilities may find alpha relative to ETFs.
“the average retail investor, if they're interested in participating in the space should be buying ETFs”
Scaled indoor cultivation skill is a hard-to-replicate edge for MSOs over subscale growers.
- MSOs are generally the best growers because scaling indoor cultivation is hard, and dispensaries increasingly stock MSO product over craft growers because subscale players deliver inconsistent quality and delivery.
“there's inconsistent quality and delivery from subscale players who simply don't know what they're doing”
- Cannabis is perishable because flower dries and loses color and stickiness, so retailers typically hold about 15 to 20 days of inventory, which is also constrained by store space.
“retail stores will keep 15 to 20 days of inventory on hand”
- Growing quality cannabis consistently is exceedingly difficult, and the cost of capital is high because federal rules block cheaper debt, which limits the ability to hire the high-quality growers that determine success.
“Growing quality cannabis that can sell consistently is exceedingly difficult”
- New investors who tour cannabis growing facilities often mistake poor operations for success, while an experienced investor can spot mold, leaks, overgrown plants, and inattentive staff that signal weak securities.
“I can see mold growing on this plant. I can see a leak in the ceiling on this plant”
- The most important input in cannabis is the grower, but high cost of capital and lack of equity upside mean high-quality growers will not join subscale players, so builders should be cautious and not expect quick riches.
“the most important component of growing cannabis is your grower and your employees”
- Growing cannabis at scale is very difficult, especially indoors, because illegal growers accustomed to small garages cannot easily manage a 20,000 square foot facility, so MSOs' operational skill is a genuine edge.
“Growing cannabis at scale is really, really difficult, especially indoor cannabis.”
Federal illegality makes operators' costs and effective tax burdens unusually high.
- Because cannabis cannot cross state lines, each state functions like its own country, so an operator must rebuild its full growing and distribution infrastructure in every state where it holds a license.
“every single state can be thought of as its own country. You're not allowed to bring product across state lines”
- Scaled MSOs earn at least 50 percent gross margins and 30 percent EBITDA margins, but because most expenses below gross profit are not tax deductible due to federal illegality, their effective tax rate runs 50 to 70 percent.
“the vast majority of expenses below gross profit are not tax deductible due to the federal illegality of cannabis. So, effectively the tax rate these MSOs are paying are 50 to 70%”
- The cost of debt for the most scaled MSOs is about 8 percent, and about 10 percent or more once other costs are included, which is prohibitively high and blocks operators from scaling, even as policymakers claim to want to help entrepreneurs.
“the cost of debt for the most scaled MSOs are 8%, but that's not even all inclusive other costs. We're probably looking at 10% cost of debt”
Incremental bills like SAFE Banking are more achievable than flawed federal scheduling and reform.
- Public support for legalization falls with age, while Senate Republicans average about 66 years old, so an older Senate that is out of step with a younger public is why comprehensive federal reform stalls and incremental, piecemeal approaches are more likely.
“Senate Republicans on average are 66 years old”
- The Marihuana Tax Act of 1937 was the first federal US law to criminalize marijuana for individual possession, using an expensive fee system to tax medicinal use.
“the Marihuana Tax Act of 1937 was the first federal US law to criminalize marijuana for individual possession”
- Cannabis was placed in Schedule I under the 1970 Controlled Substances Act alongside heroin and LSD, yet drugs in Schedules II through IV such as OxyContin, morphine, cocaine, and anabolic steroids are treated as safer or less restricted, so the scheduling logic does not hold and cannabis should be descheduled or moved to a lower schedule.
“The schedules don't make sense, and I think that there's a very broad recognition that cannabis should be scheduled at a lower rate or descheduled”
- Support for adult-use cannabis legalization in the US has risen to about 68 percent from about 40 percent a decade ago, with roughly 80 percent of Democrats, 70 percent of independents, and 50 percent of Republicans in favor.
“it's about 68% versus 40% a decade ago”
- The SAFE Banking Act would protect financial institutions that serve cannabis businesses, and passage could let banks list these shares and allow a TSX up-listing, bringing a large wave of institutional capital into a narrow, illiquid market and driving a sharp re-rating.
“SAFE Banking, if that gives cover fire to financial institutions to list these shares, that's a grand slim”
- SAFE Banking has passed the House five times with about 180 co-sponsors and broad bipartisan votes, while the MORE Act, a broader scheduling and social-equity bill, drew only one Republican co-sponsor and six Democratic votes against, so the narrower bill is the more achievable path.
“it's passed House five times, there are 180 co-sponsors for SAFE Banking”
Reinvesting in differentiated products and brands beats price cutting against the illicit market.
- Long-run pricing power will come from companies that can reinvest cash flow into differentiated products, because the real competitor is the illicit market rather than other MSOs, so cutting prices to chase share is a mistake.
“competition is not another MSO, competition is the illicit market”
- Reinvestment by MSOs will produce time-released edibles that take effect in about 15 minutes instead of 90 minutes, letting consumers dose more precisely and expanding on-premise and everyday consumption.
“there's going to be a time released edible much like time released Adderall, it'll kick in in 15 minutes”
- Because cannabis marketing is restricted, MSOs build brand by cultivating budtenders, who act as brand advocates in the same way restaurant staff recommend dishes.
“So that's their best way of marketing brands are budtenders.”
- Apple's reversal to allow cannabis delivery apps means brand building in digital channels will matter more, because consumers without a budtender need to know which brand to buy.
“Apple formerly banned apps that facilitated marijuana sales, and now allows weed delivery service apps on its platform.”
- Products must be reformulated for each state's rules, so national brands like Mindy's Edibles must prove consistent quality, flavor, and effect across markets to win consumer trust.
“every single state doesn't allow you to create the exact same product. You have to reformulate it a bit differently.”
- Each MSO chooses a north star: premium players refuse discounting while Walmart-style players cut prices, and the choice depends on the operator's long-term outcome.
“There are MSOs that want to be the Walmart of cannabis, and they're willing to cut pricing.”
Federal prohibition and banking exclusion create cash-handling danger that reform should address.
- Because most dispensaries are cash-only and only about 10 percent of US banks and credit unions serve plant-touching cannabis businesses, cash moves by armored truck and operators face heavy compliance burdens and high danger.
“Last time I checked, I want to say there were about 10% of banks and credit unions that were willing to do this”
- Dispensaries operate as cash businesses because banks will not serve them, so the cash-heavy legal market, around $25 billion, creates danger including robbery and violence that banking reform would fix.
“This is a cash business. You cannot go use a credit card at a dispensary.”
- The Controlled Substances Act of 1970 under Richard Nixon repealed the Marihuana Tax Act and classified marijuana as a Schedule I drug alongside heroin, LSD and ecstasy, asserting no medical use and high abuse potential.
“enlisted marijuana as a schedule I drug along with heroin, LSD and ecstasy”
- Comprehensive federal cannabis reform is unlikely in the near term, so incremental measures such as SAFE Banking are the realistic path to change.
“in my opinion, what we'll find is, incrementalism is the way forward”
- Roughly 10 percent of US banks and credit unions are willing to serve cannabis businesses that touch the plant, and the stringent compliance checks make this a small, comparatively lucrative niche.
“Last time I checked, I want to say there were about 10% of banks and credit unions that were willing to do this.”